<DOC>
	<DOCNO>NCT00677118</DOCNO>
	<brief_summary>The purpose study compare concurrent chemoradiotherapy plus adjuvant chemotherapy concurrent chemoradiotherapy patient locoregionally advanced NPC , order evaluate value adjuvant chemotherapy nasopharyngeal carcinoma ( NPC ) patient .</brief_summary>
	<brief_title>Adjuvant Chemotherapy Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients present non-keratinizing NPC stage T3-4N1M0/TxN2-3M0 randomly assign receive concurrent chemoradiotherapy plus adjuvant chemotherapy ( investigational arm ) concurrent chemoradiotherapy ( control arm ) . Patients arm receive radical radiotherapy cisplatin ( 40mg/m2 day 1 ) weekly radiotherapy . Patients investigational arm receive cisplatin ( 80mg/m2 day 1 ) fluorouracil ( 800mg/m2 Day 1 5 ) every four week three cycle completion radiotherapy . Patients stratify accord treatment center . The primary end point failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , distant failure-free survival ( D-FFS ) , locoregional failure-free survival ( LR-FFS ) , initial response rate treatment , toxic effect treatment compliance . All efficacy analysis conduct intention-to-treat population ; safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients newly histologically confirm nonkeratinizing carcinoma ( accord World Health Organization ( WHO ) histologically type ) 2 . Tumor stag N23or T34N1 ( accord 6th American Joint Committee Cancer stag system ) 3 . No evidence distant metastasis ( M0 ) 4 . Performance status : KPS ≥70 5 . With normal liver function test ( Alanine Aminotransferase、Aspartate Aminotransferase ≤2.5×upper limit normal ) 6 . Renal : creatinine clearance ≥60ml/min 7 . Adequate marrow : leucocyte count ≥4000/μL , hemoglobin ≥80g/L platelet count ≥100000/μL 8 . Written inform consent 1. WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . 2 . Age ≥70 &lt; 18 3 . With history renal disease 4 . Prior malignancy 5 . Previous chemotherapy radiotherapy 6 . Patient pregnant lactate 7 . Unstable cardiac disease require treatment . 8 . Emotion disturbance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Clinical trial</keyword>
</DOC>